ALDX
Aldeyra TherapeuticsยทNASDAQ
--
--(--)
--
--(--)
ALDX Profile
Aldeyra Therapeutics, Inc.
A biotechnology company developing novel therapies for immune-mediated diseases
131 Hartwell Avenue, Suite 320, Lexington, MA 02421
--
Aldeyra Therapeutics, Inc., was incorporated in Delaware on August 13, 2004. The company is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapies designed to treat immune-mediated diseases. Its approach focuses on regulating the protein system, and late-stage drug candidates include reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for retinal diseases.
